Browse by tag

aav

• Explain why there is discordance in FVIII activity after AAV gene therapy between one-stage (OS) and chromogenic substrate (CS) assays.

assay-discrepancy

• Explain why there is discordance in FVIII activity after AAV gene therapy between one-stage (OS) and chromogenic substrate (CS) assays.
• Why is there a discrepancy between clot-based one-stage assays and chromogenic assays in patients who have undergone gene therapy for hemophilia B?

diagnosis

• How can someone who has a low factor VIII level of around 40% be considered to possibly have type 2N VWD?

efanesoctocog-alfa

• Can we use Altuviiio (efanesoctocog alfa) for patients who have a history of inhibitors and underwent ITI?

extended-half-life

• Can we use Altuviiio (efanesoctocog alfa) for patients who have a history of inhibitors and underwent ITI?

f8-gene

• What is the F8 gene duplication (FVIII Padua)?

factor-ix

• Why is there a discrepancy between clot-based one-stage assays and chromogenic assays in patients who have undergone gene therapy for hemophilia B?

factor-viii

• Can we use Altuviiio (efanesoctocog alfa) for patients who have a history of inhibitors and underwent ITI?
• Explain why there is discordance in FVIII activity after AAV gene therapy between one-stage (OS) and chromogenic substrate (CS) assays.
• How can someone who has a low factor VIII level of around 40% be considered to possibly have type 2N VWD?
• What is the F8 gene duplication (FVIII Padua)?

fix-padua

• Why is there a discrepancy between clot-based one-stage assays and chromogenic assays in patients who have undergone gene therapy for hemophilia B?

fviii-padua

• What is the F8 gene duplication (FVIII Padua)?

gene-therapy

• Explain why there is discordance in FVIII activity after AAV gene therapy between one-stage (OS) and chromogenic substrate (CS) assays.
• Why is there a discrepancy between clot-based one-stage assays and chromogenic assays in patients who have undergone gene therapy for hemophilia B?

genetics

• How can someone who has a low factor VIII level of around 40% be considered to possibly have type 2N VWD?
• What is the F8 gene duplication (FVIII Padua)?

hemophilia-a

• Can we use Altuviiio (efanesoctocog alfa) for patients who have a history of inhibitors and underwent ITI?
• Explain why there is discordance in FVIII activity after AAV gene therapy between one-stage (OS) and chromogenic substrate (CS) assays.

hemophilia-b

• Why is there a discrepancy between clot-based one-stage assays and chromogenic assays in patients who have undergone gene therapy for hemophilia B?

immune-tolerance-induction

• Can we use Altuviiio (efanesoctocog alfa) for patients who have a history of inhibitors and underwent ITI?

inhibitors

• Can we use Altuviiio (efanesoctocog alfa) for patients who have a history of inhibitors and underwent ITI?

laboratory-assays

• Explain why there is discordance in FVIII activity after AAV gene therapy between one-stage (OS) and chromogenic substrate (CS) assays.
• Why is there a discrepancy between clot-based one-stage assays and chromogenic assays in patients who have undergone gene therapy for hemophilia B?

thrombophilia

• What is the F8 gene duplication (FVIII Padua)?

type-2n-vwd

• How can someone who has a low factor VIII level of around 40% be considered to possibly have type 2N VWD?

venous-thromboembolism

• What is the F8 gene duplication (FVIII Padua)?

vwd

• How can someone who has a low factor VIII level of around 40% be considered to possibly have type 2N VWD?

vwf

• How can someone who has a low factor VIII level of around 40% be considered to possibly have type 2N VWD?